kENUP Foundation: EIB and FIND back innovative plant-based reagent manufacturing in Africa to fight COVID-19 and other endemic diseases
African reagent manufacturing for rapid testing kits and treatment for COVID-19 and other endemic diseases will be transformed by construction of a new Cape Biologix Technologies facility in Mauritius.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201218005388/en/
This will enable the company to scale up innovative plant-based manufacturing and to commercialise the successful development of plant based recombinant proteins and in particular, antibodies as a spin-off from the University of Cape Town. The manufacturing facility aims to ensure the supply of crucial reagents for the production of 100 million vaccines a month for distribution across Africa, the Caribbean and Pacific.
Initiated by kENUP Foundation, new financing from the European Investment Bank (EIB) and FIND (Foundation for Innovative New Diagnostics) for the EUR 47.5 million project was formally agreed earlier today. The EIB will provide EUR 33.3 million for the specialist manufacturing plant in Mauritius. This has been complemented by EUR 3.2 million provided by FIND that is being used to fund the rapid scale-up of the pilot phase production in Cape Town, South Africa.
“Scaling up medical innovation and specialist manufacturing is crucial to control COVID-19 and combat other diseases that can be treated, but where treatment remains a limited privilege. EIB is pleased to provide EUR 33.3 million to support Cape Biologix to expand pharmaceutical production, create jobs and increase access to affordable disease testing and treatment across Africa and around the world by increasing the affordability of key proteins. This new investment is bringing world class research from laboratories in Cape Town to improve the lives of millions of people. As part of Team Europe, the EIB is committed to working together with global partners to reduce the impact of the COVID-19 pandemic and improve public health in the years ahead.” said Ambroise Fayolle, EIB Vice President.
“Local innovation and manufacturing are critical to ensuring that quality tests can reach all who need them. We are very happy to build on our longstanding relationships in South Africa to work together on this transformative project with Cape Bio, in partnership with the EIB, translating exciting research into tangible products that will benefit everyone in the region. Building local capacity is not only needed today for COVID-19, but will also improve South Africa’s preparedness to respond to future threats.” said Dr Catharina Boehme, CEO of FIND.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TX-GPD-COMPANIES22.1.2021 14:35:10 CET | Press release
GPD Companies, Inc. to Acquire Distrupol
TX-SCHLUMBERGER22.1.2021 12:52:04 CET | Press release
Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results
CA-ANDERSEN-GLOBAL22.1.2021 11:04:11 CET | Pressemeddelelse
Andersen Global styrker sin afrikanske platform med Kashadah & Co.
JEOL22.1.2021 07:02:12 CET | Press release
JEOL: Release of a New Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)
DAWEX/NUMALIM/ORANGE22.1.2021 01:58:07 CET | Press release
NumAlim Selects Dawex and Orange Business Services for its Data and Services Exchange Platform
VIIV-HEALTHCARE21.1.2021 23:14:12 CET | Press release
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
DE-INCYTE21.1.2021 22:32:11 CET | Press release
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom